Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma

Journal of Nuclear Medicine

Volumn 54, Issue 2, 2013, Pages 229-235

  Rapp, Marion ^a   Heinzel, Alexander ^b   Galldiks, Norbert ^c,d   Stoffels, Gabriele ^c   Felsberg, Jörg ^a   Ewelt, Christian ^e   Sabel, Michael ^a   Steiger, Hans J ^a   Reifenberger, Guido ^a   Beez, Thomas ^a   Coenen, Heinz H ^c   Floeth, Frank W ^a,f   Langen, Karl Josef ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f St Vinzenz Hosp   (Germany)

Author keywords

18F FET PET; Cerebral lesions; O (2 18F fluoroethyl) L tyrosine; Tumor

Indexed keywords

O (2 FLUOROETHYL)TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; DRUG DERIVATIVE; TYROSINE;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; CANCER GRADING; CANCER LOCALIZATION; CHILD; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AREA UNDER THE CURVE; BRAIN TUMOR; METHODOLOGY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TYROSINE;

MLCS; MLOWN;

EID: 84873536915     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.109603     Document Type: Article

References (27)

1. Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics. 2009;6:465-477.
2. 18F]fluoroethyl) -L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
3. 18F]fluoroethyl-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53:1048-1057.
4. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464-1470.
5. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1-18.
6. 18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287-294.
7. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
8. 11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049-1058.
9. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322.
10. Pichler R, Dunzinger A, Wurm G, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging. 2010;37:1521-1528.
11. 18F-fluoro-ethyltyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med. 2012;53:207-214.
12. 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57:853-856.
13. Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933-1942.
14. Jansen NL, Graute V, Armbruster L, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012;39:1021-1029.
15. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)- L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519-527.
16. 18F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779-787.
17. Pauleit D, Floeth F, Tellmann L, et al. Comparison of O-(2-18F-fluoroethyl)-Ltyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med. 2004;45:374-381.
18. 18F-FET PET differentiation of ringenhancing brain lesions. J Nucl Med. 2006;47:776-782.
19. 18F] fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318-327.
20. 18F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging. 2011;38:731-741.
21. Plotkin M, Blechschmidt C, Auf G, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 2010;20:2496-2502.
22. Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol. 2008;88:205-210.
23. Heinzel A, Stock S, Langen KJ, Müller D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging. 2012;39:1089-1096.
24. 18F] fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32:422-429.
25. 18F]fluoroethyl)-Ltyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011;36:841-847.
26. 18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-oncol. 2011;13:307-316.
27. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393-403.